Missed ANDA Nods Mostly Due To 'Imminent Approval'
FDA Says ANDA User Fee Misses Are Mostly Part Of 'Imminent Approval' Process
Executive Summary
US FDA will miss goal dates to reach speedier generic drug application approvals, but says decisions will be case by case.